Stock Events

Stock Events

Aurinia Pharmaceuticals 

$14.86
133
+$0.36+2.48% Friday 00:23

Statistics

Day High
14.86
Day Low
14.86
52W High
-
52W Low
-
Volume
26
Avg. Volume
-
Mkt Cap
1.98B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
0.16
0.62
1.07
1.53
Expected EPS
0.195
Actual EPS
N/A

Financials

101.47%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
566.11MRevenue
574.4MNet Income

Analyst Ratings

$17.33Average Price Target
The highest estimate is 21.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AUPH.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline develops treatments in areas similar to Aurinia, including autoimmune diseases, making them a direct competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes in the immunology space, offering drugs that could be alternatives to Aurinia's products.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad portfolio that includes treatments for autoimmune diseases, directly competing with Aurinia's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a strong presence in the immunology and oncology sectors, areas where Aurinia is also aiming to make an impact.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on novel therapeutics in areas including inflammation, which overlaps with Aurinia's focus on autoimmune diseases.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the autoimmune disease market.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a range of treatments for autoimmune diseases, competing with Aurinia's lupus nephritis treatment.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a focus on inflammatory and respiratory diseases, making it a competitor in the autoimmune treatment market.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca has a diverse portfolio that includes treatments for lupus, directly competing with Aurinia's lupus nephritis drug.
Roche
RHHBY
Mkt Cap258.9B
Roche, through its Genentech division, develops medications for autoimmune diseases, including lupus, making it a competitor.

About

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Show more...
CEO
Mr. Peter S. Greenleaf M.B.A.
Employees
300
Country
CA
ISIN
CA05156V1022

Listings

LSE
GB
0UJF.LSE
F
DE
IKAP.F
BOATS
BOATS
AUPH.BOATS
XNAS
US
AUPH

0 Comments

Share your thoughts

FAQ

What is Aurinia Pharmaceuticals stock price today?▼
The current price of AUPH.BOATS is $14.86 USD — it has increased by +2.48% in the past 24 hours. Watch Aurinia Pharmaceuticals stock price performance more closely on the chart.
What is Aurinia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aurinia Pharmaceuticals stocks are traded under the ticker AUPH.BOATS.
What is Aurinia Pharmaceuticals market cap?▼
Today Aurinia Pharmaceuticals has the market capitalization of 1.98B
When is the next Aurinia Pharmaceuticals earnings date?▼
Aurinia Pharmaceuticals is going to release the next earnings report on April 30, 2026.
What were Aurinia Pharmaceuticals earnings last quarter?▼
AUPH.BOATS earnings for the last quarter are 1.53 USD per share, whereas the estimation was 0.22 USD resulting in a +606.15% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aurinia Pharmaceuticals revenue for the last year?▼
Aurinia Pharmaceuticals revenue for the last year amounts to 566.11M USD.
What is Aurinia Pharmaceuticals net income for the last year?▼
AUPH.BOATS net income for the last year is 574.4M USD.
How many employees does Aurinia Pharmaceuticals have?▼
As of April 05, 2026, the company has 300 employees.
In which sector is Aurinia Pharmaceuticals located?▼
Aurinia Pharmaceuticals operates in the Other sector.
When did Aurinia Pharmaceuticals complete a stock split?▼
Aurinia Pharmaceuticals has not had any recent stock splits.
Where is Aurinia Pharmaceuticals headquartered?▼
Aurinia Pharmaceuticals is headquartered in Victoria, CA.